Aptevo Therapeutics APVO shares are trading higher on Tuesday after the company announced the first complete remission in a patient was observed in the ongoing APVO436 Phase 1 clinical trial.
Aptevo Therapeutics is a biosciences company. The company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline product includes Otlertuzumab, APVO414, Multiple ADAPTIR Candidates, ALG.APV-527, APVO436 and APVO210.
Aptevo Therapeutics shares were trading up 19.37% at $7.52 on Tuesday during the time of publication. The stock has a 52-week high of $11.73 and a 52-week low of $2.94.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
